EVENT BASKET: 0 ITEMS
login
  • Text size small
  • Text size large
TEXT SIZE
The British Society for Rheumatology
  • About us
  • Join BSR
  • Resources
  • Education and Events
  • Patient information
  • BHPR
  • Members
  • Guidelines
  • Policy
  • News
    • Updated swine flu advice from DH - Dec 2009
    • BSR statement on NICE decision on use of Certolizumab pegol for rheumatoid arthritis
    • BSR response to report from the Public Accounts Committee into Services for People with Rheumatoid Arthritis
    • National Clinical Director Position Statement
    • Inflammatory Arthritis - 'S' Factor awareness campaign
    • BSR Statement on NICE FAD on adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis (RA) after the failure of a TNF inhibitor
    • NICE FAD on Tocilizumab for the treatment of RA
  • Useful links
  • password test
  • Home
  • Resources
  • News
  • EMEA Announcement on NSAIDS
Printer Friendly

EMEA Announcement on NSAIDS

25 October 2006

The European Medicines Agency (EMEA) and the Medicines and Healthcare products Regulatory Agency (MHRA) issued an announcement yesterday on updated safety information regarding Non Steroidal Anti-Inflammatory Drugs (NSAIDs) following the consideration of new evidence. View the EMEA's announcement on NSAIDs.

The MHRA has also sent notification to healthcare professionals in the form of a letter and question and answer document:
View MHRA's letter to health professionals
View MHRA's Q & A document


  • Contact us
  • Sitemap
  • BSR, Bride House, 18-20 Bride Lane, London, EC4Y 8EE.
  • Telephone: +44 (0) 20 7842 0900
  • Facsimile: +44 (0) 20 7842 0901
  • Email: bsr@rheumatology.org.uk
  • VAT No.: 404 5637 66, Company Reg No.: 3470316, Charity No.: 1067124
  • Terms & conditions
  • Privacy
  • Credits
  • Website design agency services by dotAgency